Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design Arno de Wilde, Ingrid S. van Maurik, Marleen Kunneman, Femke Bouwman, Marissa.

Slides:

Advertisements

Similar presentations

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Advertisements

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep

Use of Doppler Techniques (Continuous-Wave, Pulsed-Wave, and Color Flow Imaging) in the Noninvasive Hemodynamic Assessment of Congenital Heart Disease.

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Middle age self-report risk score predicts cognitive functioning and dementia in 20– 40 years Eero Vuoksimaa, Juha O. Rinne, Noora Lindgren, Kauko Heikkilä,

Volume 3, Issue 4, Pages (November 2017)

Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer’s disease study Wesley.

Volume 3, Issue 1, Pages (January 2017)

Volume 3, Issue 2, Pages (June 2017)

Flora H. Duits, Niels D. Prins, Afina W. Lemstra, Yolande A. L

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

A case report of locally advanced triple negative breast cancer showing pathological complete response to weekly paclitaxel with bevacizumab treatment.

Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample Marie Eckerström,

Neuroticism, depression, and anxiety traits exacerbate the state of cognitive impairment and hippocampal vulnerability to Alzheimer's disease Valérie.

Volume 3, Issue 2, Pages (June 2017)

Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib C. Leitner, R. von Moos,

Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints Argonde C. van Harten, Pieter Jelle Visser,

Sietske A. M. Sikkes, Elly S. M. de Lange-de Klerk, Yolande A. L

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

A NOVEL NEUROIMAGING APPROACH TO CAPTURE COGNITIVE RESERVE

Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire Roos J.

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

Volume 3, Issue 2, Pages (June 2017)

Multidimensional assessment of challenging behaviors in advanced stages of dementia in nursing homes—The insideDEM framework Stefan Teipel, Christina.

Alzheimer’s disease core biomarkers and prediction of dementia in MCI: The effect of age at onset Anna Caroli, Samantha Galluzzi, Clarissa Ferrari, Annapaola.

A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission.

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Marjolein Bulk, Linda van der Graaf, Walid M

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment Sanna-Kaisa Herukka,

Colin Groot, Chris W. J. van der Weijden, Wiesje M

Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline Sander C.J.

Volume 2, Issue 1, Pages (January 2016)

Volume 3, Issue 1, Pages (January 2017)

Ben Sherwood, Andrew Xiao-Hua Zhou, Sandra Weintraub, Lan Wang

Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin Eva Carro, Fernando Bartolomé, Félix Bermejo-Pareja,

Scared to the Marrow: Pitfalls and Pearls in Renal Imaging

Functional limitations and health care resource utilization for individuals with cognitive impairment without dementia: Findings from a United States.

Erosion of lumbar vertebral bodies from a chronic contained rupture of an abdominal aortic pseudoaneurysm W. Andrew Oldenburg, MD, Tariq Almerey, MD

Early Dementia Distinguishing AD From MCI

Alzheimer's disease drug development pipeline: 2018

Aniruddh Kapoor, Laurence Kinsella Clinical Neurophysiology Practice

Identifying and validating biomarkers for Alzheimer's disease

E. Bronska, J. Kalmusova, O. Dzupova, V. Maresova, P. Kriz, J. Benes

Identifying and validating biomarkers for Alzheimer's disease

Fusion of deep learning models of MRI scans, Mini–Mental State Examination, and logical memory test enhances diagnosis of mild cognitive impairment Shangran.

Interest of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for the diagnosis of relapse in patients with spinal infection: a.

A. Ferroni, H. Al Khoury, C. Dana, G. Quesne, P. Berche, C. Glorion, Z

C. P. Bleeker-Rovers, A. Warris, J. P. H. Drenth, F. H. M. Corstens, W

Erosion of lumbar vertebral bodies from a chronic contained rupture of an abdominal aortic pseudoaneurysm W. Andrew Oldenburg, MD, Tariq Almerey, MD

Pneumococcal aortitis, report of a case with emphasis on the contribution to diagnosis of positron emission tomography using fluorinated deoxyglucose

Tharick A. Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L

S. Imbert, J.-Y. Brossas, M. Palous, I. Joly, I. Meyer, A. Fekkar

Gross tumour delineation on computed tomography and positron emission tomography- computed tomography in oesophageal cancer: A nationwide study M.E. Nowee,

Dysarthria and Apraxia of Speech Associated With FK-506(Tacrolimus)

Salvage Operation in Case of Oligometastatic Disease

A Template for New Drugs against Alzheimer’s Disease

Repeat lumbar puncture in adults with bacterial meningitis

Evaluation of diagnostic tests

Mark A. Marinella, MD, Kenneth Greene, MD Mayo Clinic Proceedings

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Idiopathic Intracranial Hypertension

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

GREY MATTER CONNECTIVITY IS ASSOCIATED WITH CLINICAL PROGRESSION IN NON-DEMENTED, AMYLOID POSITIVE PATIENTS Betty M. Tijms, Mara ten Kate, Sander C.J.

Suzanne E. Schindler, Julia D. Gray, Brian A

European Urology Oncology

CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER.

Gradually Progressive Dementia Without Discrete Cerebrovascular Events in a Patient With Sneddon's Syndrome R. Alan Wright, M.B.,CH.B., M.D., Emre Kokmen,

Presentation transcript:

Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design Arno de Wilde, Ingrid S. van Maurik, Marleen Kunneman, Femke Bouwman, Marissa Zwan, Eline A.J. Willemse, Geert Jan Biessels, Mirella Minkman, Ruth Pel, Niki S.M. Schoonenboom, Ellen M.A. Smets, Mike P. Wattjes, Frederik Barkhof, Andrew Stephens, Erik J. van Lier, Richard Batrla-Utermann, Philip Scheltens, Charlotte E. Teunissen, Bart N.M. van Berckel, Wiesje M. van der Flier Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring Volume 6, Pages 143-151 (January 2017) DOI: 10.1016/j.dadm.2017.01.003 Copyright © 2017 The Authors Terms and Conditions

Fig. 1 Patient journey in memory clinics. (A) Current patient journey in memory clinics. (B) ABIDE patient journey in memory clinics. Abbreviations: ABIDE, Alzheimer's biomarkers in daily practice; CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; PET, positron emission tomography. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 2017 6, 143-151DOI: (10.1016/j.dadm.2017.01.003) Copyright © 2017 The Authors Terms and Conditions

Fig. 2 Hierarchy of ABIDE objectives. Abbreviation: ABIDE, Alzheimer's biomarkers in daily practice; CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; PET, positron emission tomography. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 2017 6, 143-151DOI: (10.1016/j.dadm.2017.01.003) Copyright © 2017 The Authors Terms and Conditions